The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen’s Anemia Drug, Corvus Shelves COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 15)
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 14)
12 Health Care Stocks Moving In Wednesday’s After-Market Session
Gainers
Zosano Pharma (NASDAQ:ZSAN) stock rose 22.29% to $0.91 during Wednesday's after-market session. This security traded at a volume of 1.8 million shares come close, making up 69.15% of its average volume over the last 100 days. The company's market cap stands at $97.1 million.
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's morning session saw 16 companies set new 52-week lows.
The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 24)
Nymox Announces Date For Fexapotide Filing; Will File For Marketing Approval Before End Of Summer, On Or Before Sept. 15, 2021
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) (the "Company") is pleased to announce that it will be filing for marketing approval of Fexapotide Triflutate for BPH before the end of the summer, on or before 15